Teva Pharma (TEVA) Announces NEJM Publishes Data from Pivotal Phase III Trial of Fremanezumab for Preventive Treatment of Chronic Migraine
Tweet Send to a Friend
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the publication of data from the pivotal Phase III HALO ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
